SB1518 (Pacritinib)
-
Catalog number2450-5
-
PricePlease ask
-
Size5 mg
-
-
Alternative_name11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
-
DescriptionA potent JAK2/FLT3 inhibitor. Displays equipotent activity against JAK2 (I₅₀ = 23 nM) and FLT3 (IC₅₀ = 22 nM). SB1518 displays potent anti-proliferative effects on myeloid and lymphoid cell lines driven by mutant or wild-type JAK2 or FLT3, resulting from cell cycle arrest and induction of apoptosis.
-
CAS Number937272-79-2
-
Structure AvailableYes
-
Salt FormNo
-
Molecular FormulaC₂₈H₃₂N₄O₃
-
Molecular Weight472.58
-
Cell PermeableYes
-
Purity≥98% by HPLC
-
SolubilitiesDMSO
-
HandlingProtect from air and light
-
Tag LineApotent JAK2/FLT3 inhibitor
-
Storage Condition-20°C
-
Shipping Conditiongel pack
-
Shelf Life24 months
-
PubChem CID46216796
-
SMILESC1CCN(C1)CCOC2=C3COCC=CCOCC4=CC=CC(=C4)C5=NC(=NC=C5)NC(=C3)C=C2
-
InChiInChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+
-
InChi KeyHWXVIOGONBBTBY-ONEGZZNKSA-N
-
MSDS AvailableYes
-
Gene target
-
Short nameSB1518 (Pacritinib)
-
Alternative nameSB1518 (Pacritinib)
-